|  |  |
| --- | --- |
| **Table 1. PATIENTS’ CHARACTERISTICS** | |
| **SEX** | |
| MALE | 43 (43.4) |
| FEMALE | 56 (56.6) |
| **AGE AT TREATMENT** | |
| MEDIAN (RANGE) | 64 (26-83) |
| **METASTATIC ONSET** | |
| METACHRONOUS | 66 (66.6) |
| SYNCHRONOUS |  |
| **HISTOTYPE** | |
| LEIOMYOSARCOMA | 34 (34.4) |
| LEIOMYOSARCOMA NAS | 17 |
| UTERINE LEIOMYOSARCOMA | 17 |
| LIPOSARCOMA | 27 (27.3) |
| WELL DIFFERENTIATED LIPOSARCOMA | 7 |
| DE DIFFERENTIATED LIPOSARCOMA | 14 |
| MYXOID LIPOSARCOMA | 2 |
| PLEOMORPHIC LIPOSARCOMA | 4 |
| OTHERS | 38 (38.3) |
| ANGIOSARCOMA | 7 |
| DSRC | 2 |
| FIBROSARCOMA | 2 |
| MYXOFIBROSARCOMA | 4 |
| MPNST | 1 |
| RHABDOMYOSARCOMA | 1 |
| ALVEOLAR SARCOMA | 1 |
| EPITHELIOID SARCOMA | 1 |
| SYNOVIAL SARCOMA | 4 |
| HIGH GRADE SES | 1 |
| SFT | 4 |
| UPS | 10 |
| **TUMOR BURDEN** | |
| SINGLE METASTASIS | 1 (1.0) |
| OLIGOMETASTATIC | 52 (53.1) |
| DISSEMINATED | 45 (45.9) |
| **GRADING** | |
| G1 | 6 (6.2) |
| G2 | 22 (22.7) |
| G3 | 69 (71.1) |
| **PS ECOG** | |
| 0 | 26 (6.2) |
| 1 | 63 (63.7) |
| 2 | 69 (71.1) |
| **FIRST-LINE TREATMENT** | |
| ADRIAMYCIN | 39 (39.4) |
| ADRIAMYCIN + DACARBAZINE | 11 (11.1) |
| EI | 47 (47.5) |
| VAI-IE | 2 (2.1) |